Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia

Journal of Clinical Microbiology

Volumn 49, Issue 9, 2011, Pages 3300-3308

  Arendrup, Maiken Cavling ^a   Sulim, Sofia ^b   Holm, Anette ^c   Nielsen, Lene ^d   Nielsen, Susanne Dam ^e   Knudsen, Jenny Dahl ^e   Drenck, Niels Erik ^f   Christensen, Jens Jørgen ^a   Johansen, Helle Krogh ^g  

^a STATENS SERUM INSTITUT   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f ROSKILDE HOSPITAL   (Denmark)

^g Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADULT; AGE DISTRIBUTION; AGED; ANALYTICAL EQUIPMENT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTEREMIA; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CLINICAL FEATURE; CONTROLLED STUDY; DENMARK; DISEASE SEVERITY; DRUG CHOICE; FEMALE; FUNGAL COLONIZATION; FUNGEMIA; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HEMATOLOGY; HUMAN; INCUBATION TIME; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROBIOLOGICAL EXAMINATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SPECIES DISTRIBUTION; SURGICAL PATIENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; FUNGEMIA; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RISK FACTORS; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME; YOUNG ADULT;

CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; SACCHAROMYCES CEREVISIAE;

EID: 80052219362     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00179-11     Document Type: Article

References (57)

1. Abi-Said, D., et al. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128.
2. Ahlquist, A., et al. 2009. Epidemiology of candidemia in metropolitan Atlanta and Baltimore City and County: preliminary results of populationbased active, laboratory surveillance - 2008-2009, abstr. M-1241. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
3. Almirante, B., et al. 2006. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 44:1681-1685. (Pubitemid 43726255)
4. Almirante, B., et al. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835.
5. Andes, D., et al. 2010. Impact of therapy on mortality across Candida spp. in patients with invasive candidiasis from randomized clinical trials: a patient-level analysis, abstr. M-1312. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
6. Arendrup, M., T. Horn, and N. Frimodt-Moller. 2002. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 30:286-291.
7. Arendrup, M. C. 2010. Epidemiology of invasive candidiasis. Curr. Opin. Crit. Care 16:445-452.
8. Arendrup, M. C., et al. 2007. Diagnostics of fungal infections in the Nordic countries: we still need to improve! Scand. J. Infect. Dis. 39:337-343.
9. Arendrup, M. C., et al. 2005. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J. Clin. Microbiol. 43:4434-4440.
10. Arendrup, M. C., et al. 2008. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14:487-494.
11. Arendrup, M. C., et al. 2010. National surveillance of fungemia in Denmark (2004 to 2009). J. Clin. Microbiol. 49:325-334.
12. Asmundsdottir, L. R., et al. 2008. Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin. Infect. Dis. 47:e17-e24.
13. Bassetti, M., et al. 2009. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J. Antimicrob. Chemother. 64:625-629.
14. Boo, T. W., B. O'Reilly, J. O'Leary, and B. Cryan. 2005. Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. Mycoses 48:251-259. (Pubitemid 40965944)
15. Brillowska-Dabrowska, A., O. Bergmann, I. M. Jensen, J. O. Jarlov, and M. C. Arendrup. 2010. Typing of Candida isolates from patients with invasive infection and concomitant colonization. Scand. J. Infect. Dis. 42:109-113.
16. Chen, S., et al. 2006. Active surveillance for candidemia, Australia. Emerg. Infect. Dis. 12:1508-1516.
17. Cisterna, R., et al. 2010. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J. Clin. Microbiol. 48:4200-4206.
18. Cuenca-Estrella, M., et al. 2007. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 13:1018-1022.
19. Dalle, F., et al. 2000. Comparative genotyping of Candida albicans bloodstream and nonbloodstream isolates at a polymorphic microsatellite locus. J. Clin. Microbiol. 38:4554-4559.
20. Garey, K. W., et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
21. Gudlaugsson, O., et al. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
22. Hachem, R., H. Hanna, D. Kontoyiannis, Y. Jiang, and I. Raad. 2008. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493-2499.
23. Hajjeh, R. A., et al. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527.
24. Hassan, I., G. Powell, M. Sidhu, W. M. Hart, and D. W. Denning. 2009. Excess mortality, length of stay and cost attributable to candidaemia. J. Infect. 59:360-365.
25. Holzknecht, B. J., et al. 13 November 2010. Decreasing candidemia rate in abdominal surgery patients after introduction of fluconazole prophylaxis. Clin. Microbiol. Infect. [Epub ahead of print.] doi:10.1111/j.1469-0691.2010.03422.x.
26. Horvath, L. L., B. J. George, C. K. Murray, L. S. Harrison, and D. R. Hospenthal. 2004. Direct comparison of the BACTEC 9240 and BacT/ ALERT 3D automated blood culture systems for Candida growth detection. J. Clin. Microbiol. 42:115-118.
27. Kibbler, C. C., et al. 2003. Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect. 54:18-24.
28. Lass-Florl, C., et al. 2003. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann. Hematol. 82:565-569.
29. Laupland, K. B., D. B. Gregson, D. L. Church, T. Ross, and S. Elsayed. 2005. Invasive Candida species infections: a 5 year population-based assessment. J. Antimicrob. Chemother. 56:532-537.
30. Leon, C. M., et al. 2009. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit. Care Med. 37: 1624-1633.
31. Manzoni, P., et al. 2008. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr. Infect. Dis. J. 27:731-737.
32. Marr, K. A., K. Seidel, T. C. White, and R. A. Bowden. 2000. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181:309-316.
33. Marriott, D. J., et al. 2009. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit. Care 13:R115.
34. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
35. Nace, H. L., D. Horn, and D. Neofytos. 2009. Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007. Diagn. Microbiol. Infect. Dis. 64:289-294.
36. Ortega, M., et al. 2010. Candida spp. bloodstream infection: influence of antifungal treatment on outcome. J. Antimicrob. Chemother. 65:562-568.
37. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
38. Pappas, P. G., et al. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
39. Pittet, D., M. Monod, P. M. Suter, E. Frenk, and R. Auckenthaler. 1994. Candida colonization and subsequent infections in critically ill surgical patients. Ann. Surg. 220:751-758.
40. Playford, E. G., G. R. Nimmo, M. Tilse, and T. C. Sorrell. 2010. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. J. Hosp. Infect. 76:46-51.
41. Poikonen, E., O. Lyytikainen, V. J. Anttila, and P. Ruutu. 2003. Candidemia in Finland, 1995-1999. Emerg. Infect. Dis. 9:985-990.
42. Poikonen, E., O. Lyytikainen, and P. Ruutu. 2009. Candidaemia in Finland, 1995-1999 versus 2004-2007, abstr. P1961. Abstr. Eur. Conf. Clin. Microbiol. Infect. Dis.
43. Reboli, A. C., et al. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
44. Rex, J. H., et al. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36:1221-1228.
45. Rodriguez-Tudela, J. L., et al. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
46. Sandven, P., et al. 2006. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 44:1977-1981.
47. Sipsas, N. V., et al. 2009. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115:4745-4752.
48. Slavin, M. A., et al. 2010. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J. Antimicrob. Chemother. 65:1042-1051.
49. St.-Germain, G., et al. 2008. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can. J. Infect. Dis. Med. Microbiol. 19:55-62.
50. Taur, Y., N. Cohen, S. Dubnow, A. Paskovaty, and S. K. Seo. 2010. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob. Agents Chemother. 54:184-190.
51. Tortorano, A. M., et al. 2002. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J. Hosp. Infect. 51:297-304.
52. Tortorano, A. M., et al. 2004. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 23:317-322.
53. Trick, W. E., S. K. Fridkin, J. R. Edwards, R. A. Hajjeh, and R. P. Gaynes. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35:627-630.
54. Viscoli, C., et al. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1071-1079.
55. Weinberger, M., et al. 2005. Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality. J. Hosp. Infect. 61:146-154.
56. Wingard, J. R., et al. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.
57. Zaoutis, T. E., et al. 2005. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41:1232-1239.